These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26625295)

  • 1. Crystallographic insights into the structure-activity relationships of diazaborine enoyl-ACP reductase inhibitors.
    Jordan CA; Sandoval BA; Serobyan MV; Gilling DH; Groziak MP; Xu HH; Vey JL
    Acta Crystallogr F Struct Biol Commun; 2015 Dec; 71(Pt 12):1521-30. PubMed ID: 26625295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of the structure-activity relationship for diazaborine inhibition of Escherichia coli enoyl-ACP reductase.
    Levy CW; Baldock C; Wallace AJ; Sedelnikova S; Viner RC; Clough JM; Stuitje AR; Slabas AR; Rice DW; Rafferty JB
    J Mol Biol; 2001 May; 309(1):171-80. PubMed ID: 11491286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.
    Bergler H; Fuchsbichler S; Högenauer G; Turnowsky F
    Eur J Biochem; 1996 Dec; 242(3):689-94. PubMed ID: 9022698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, biological evaluation and in silico molecular modeling of pyrrolyl benzohydrazide derivatives as enoyl ACP reductase inhibitors.
    Joshi SD; Dixit SR; Kulkarni VH; Lherbet C; Nadagouda MN; Aminabhavi TM
    Eur J Med Chem; 2017 Jan; 126():286-297. PubMed ID: 27889632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI).
    Mehboob S; Song J; Hevener KE; Su PC; Boci T; Brubaker L; Truong L; Mistry T; Deng J; Cook JL; Santarsiero BD; Ghosh AK; Johnson ME
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1292-6. PubMed ID: 25677657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitor binding studies on enoyl reductase reveal conformational changes related to substrate recognition.
    Roujeinikova A; Sedelnikova S; de Boer GJ; Stuitje AR; Slabas AR; Rafferty JB; Rice DW
    J Biol Chem; 1999 Oct; 274(43):30811-7. PubMed ID: 10521472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor.
    Schiebel J; Chang A; Shah S; Lu Y; Liu L; Pan P; Hirschbeck MW; Tareilus M; Eltschkner S; Yu W; Cummings JE; Knudson SE; Bommineni GR; Walker SG; Slayden RA; Sotriffer CA; Tonge PJ; Kisker C
    J Biol Chem; 2014 Jun; 289(23):15987-6005. PubMed ID: 24739388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of a hybrid genetic system to study the functional relationship between prokaryotic and plant multi-enzyme fatty acid synthetase complexes.
    Kater MM; Koningstein GM; Nijkamp HJ; Stuitje AR
    Plant Mol Biol; 1994 Aug; 25(5):771-90. PubMed ID: 8075395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vibrio cholerae FabV defines a new class of enoyl-acyl carrier protein reductase.
    Massengo-Tiassé RP; Cronan JE
    J Biol Chem; 2008 Jan; 283(3):1308-1316. PubMed ID: 18032386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FabI (enoyl acyl carrier protein reductase) - A potential broad spectrum therapeutic target and its inhibitors.
    Rana P; Ghouse SM; Akunuri R; Madhavi YV; Chopra S; Nanduri S
    Eur J Med Chem; 2020 Dec; 208():112757. PubMed ID: 32883635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of aryl ether inhibitors of the Bacillus anthracis enoyl-ACP reductase.
    Tipparaju SK; Mulhearn DC; Klein GM; Chen Y; Tapadar S; Bishop MH; Yang S; Chen J; Ghassemi M; Santarsiero BD; Cook JL; Johlfs M; Mesecar AD; Johnson ME; Kozikowski AP
    ChemMedChem; 2008 Aug; 3(8):1250-68. PubMed ID: 18663709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis and mechanism of enoyl reductase inhibition by triclosan.
    Stewart MJ; Parikh S; Xiao G; Tonge PJ; Kisker C
    J Mol Biol; 1999 Jul; 290(4):859-65. PubMed ID: 10398587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenylimidazole derivatives as specific inhibitors of bacterial enoyl-acyl carrier protein reductase FabK.
    Ozawa T; Kitagawa H; Yamamoto Y; Takahata S; Iida M; Osaki Y; Yamada K
    Bioorg Med Chem; 2007 Dec; 15(23):7325-36. PubMed ID: 17892940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular genetic analysis of enoyl-acyl carrier protein reductase inhibition by diazaborine.
    de Boer GJ; Pielage GJ; Nijkamp HJ; Slabas AR; Rafferty JB; Baldock C; Rice DW; Stuitje AR
    Mol Microbiol; 1999 Jan; 31(2):443-50. PubMed ID: 10027962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atromentin and leucomelone, the first inhibitors specific to enoyl-ACP reductase (FabK) of Streptococcus pneumoniae.
    Zheng CJ; Sohn MJ; Kim WG
    J Antibiot (Tokyo); 2006 Dec; 59(12):808-12. PubMed ID: 17323650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacophore and molecular docking guided 3D-QSAR study of bacterial enoyl-ACP reductase (FabI) Inhibitors.
    Lu X; Lv M; Huang K; Ding K; You Q
    Int J Mol Sci; 2012; 13(6):6620-6638. PubMed ID: 22837653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panosialins, inhibitors of enoyl-ACP reductase from Streptomyces sp. AN1761.
    Kwon YJ; Sohn MJ; Oh T; Cho SN; Kim CJ; Kim WG
    J Microbiol Biotechnol; 2013 Feb; 23(2):184-8. PubMed ID: 23412060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural characterization of Porphyromonas gingivalis enoyl-ACP reductase II (FabK).
    Hevener KE; Santarsiero BD; Lee H; Jones JA; Boci T; Johnson ME; Mehboob S
    Acta Crystallogr F Struct Biol Commun; 2018 Feb; 74(Pt 2):105-112. PubMed ID: 29400320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniae reveals the binding mode of an inhibitor.
    Saito J; Yamada M; Watanabe T; Iida M; Kitagawa H; Takahata S; Ozawa T; Takeuchi Y; Ohsawa F
    Protein Sci; 2008 Apr; 17(4):691-9. PubMed ID: 18305197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase.
    Neckles C; Eltschkner S; Cummings JE; Hirschbeck M; Daryaee F; Bommineni GR; Zhang Z; Spagnuolo L; Yu W; Davoodi S; Slayden RA; Kisker C; Tonge PJ
    Biochemistry; 2017 Apr; 56(13):1865-1878. PubMed ID: 28225601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.